“Breast Cancer Talk”: Nursing Perspectives on HER2-Targeted Agents in Breast Cancer

EP. 1: Practical Management of Early Stage HER2+ Breast Cancer

ByMadelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology,Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center,Susan Hays, ANP, Washington University Siteman Cancer Center,Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute

September 23rd 2020

EP. 2: HER2-targeted Therapy: Routes of Administration

ByMadelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology,Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center,Susan Hays, ANP, Washington University Siteman Cancer Center,Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute

September 23rd 2020

EP. 3: FDA-approved Therapies for Relapsed/Refractory HER2+ mBC

ByMadelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology,Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center,Susan Hays, ANP, Washington University Siteman Cancer Center,Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute

September 23rd 2020

EP. 4: Management of Adverse Effects in R/R HER2+ mBC

ByMadelaine Kuiper, NP, UCLA Santa Monica Hematology/Oncology,Loyda E. Braithwaite, NP, University of Wisconsin Carbone Cancer Center,Susan Hays, ANP, Washington University Siteman Cancer Center,Elahe Salehi, DNP, ANP-BC, Dana-Farber Cancer Institute

September 23rd 2020

Trending on OncLive

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

The OncFive: Top Oncology Articles for the Week of 9/27/2026

AUA Releases Guideline Amendment for NMIBC

Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer

FLORA-2 Updates at World Lung: Biomarker Analysis, Safety Follow-Up, and ctDNA Monitoring